Earnings Call · Q4 FY2025·2026-02-19

Q4 25EPS -100.00%*·Rev n/aQ3 25EPS -100.00%*·Rev n/aQ2 25EPS +46.18%·Rev n/aQ1 25EPS +12.40%·Rev n/a⚠ consensus missing

MADRIGAL PHARMACEUTICALS, INC. MDGL

Tina E. Ventura — Investor Relations or Corporate Communications

William J. Sibold — Chief Executive Officer

Mardi C. Dier — Chief Financial Officer

−11.1%1d on move date−10.8% vs SPY3d−10.9%5d−11.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more MDGL calls or request research access.

More MDGL calls Browse calls Request research access